Last reviewed · How we verify
AZD1222
At a glance
| Generic name | AZD1222 |
|---|---|
| Also known as | ChAdOx1 nCoV-19, AZ_VACCINE_COVID-19, (previously called ChAdOx1 nCoV-19) |
| Sponsor | Masaryk University |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection (PHASE1)
- EU Secondary Data Post-Authorisation Safety Study of AZD1222
- A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults (PHASE4)
- NDV-HXP-S Vaccine Clinical Trial (COVIVAC) (PHASE2)
- Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults (PHASE2,PHASE3)
- Immunogenicity of COVID-19 Vaccine on Heterologous Schedule (PHASE2)
- Study of AZD1222 for the Prevention of COVID-19 in Japan (PHASE1,PHASE2)
- Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD1222 CI brief — competitive landscape report
- AZD1222 updates RSS · CI watch RSS
- Masaryk University portfolio CI